Mr. Mark Saldanha
Managing Director and CEO
Mr. Saldanha is the founder promoter of the company. Prior to Marksans, he had been associated with Glenmark Pharmaceuticals Ltd. as a Whole Time Director. He is well versed with the overall management of the company and has vast experience across the marketing, production and finance functions.
Mr. A.S Mohanty
Mr. A.S Mohanty has joined Marksans Pharma Ltd As Executive Director at Mumbai. He has assumed the Sales, Marketing and Operations responsibilities of India and ROW.
His Last appointment was with Glenmark Pharmaceuticals Ltd Where he has served for 27 years out of total 40 years of service in Pharma industry. During this period Mr. Mohanty moved through Sales, Marketing, Operations, and International marketing. The last 9 Years was spent as Executive Director on the board of Glenmark Pharmaceuticals Ltd. With independent responsibility of India and ROW.
He is Post Graduate in Mathematics and has acquired several management certification courses from premium management institutions in India.
Mr. Sathish Kumar
MD – Marksans Pharma (UK) Ltd.
Mr. Sathish Kumar is Managing Director of Marksans Pharma (UK) Ltd. & manages Affairs of Bells & Sons (Druggists) Ltd and Relonchecm Ltd, both step down operating subsidiaries of Marksans Pharma (UK) Ltd. He has done masters in pharmacy and has over 20 years of experience in Pharma industry working across Production, Planning and inventory Management, Formulation development, Regulatory, Technical, Commercial, Sales and Business development.
Mr. David Mohammed
MD - Nova Pharmaceuticals Australasia Pty Ltd.
Mr. Mohammed held the positions of the Managing Director Australasia and Marketing Director Asia, Africa and Australasia at Valeant Pharmaceuticals for over 7 years, prior to Nova Pharmaceuticals.
Mr. Jitendra M Sharma
Chief Financial Officer
Mr. Sharma is a qualified chartered accountant and cost accountant with over 20 years experience in financial functions including treasury and forex management. He has expertise in the areas of costing, fund raising and internal control systems. He is a director in MPL’s subsidiaries, Marksans Pharma (UK) Ltd, Marksans Pharma Inc. (USA), Nova Pharmaceuticals, Australia and Relonchem, UK.